Pre-tax income for the fourth quarter of 2007 totaled $409,000, compared to $650,000 for the prior year's fourth quarter. Net income for the quarter was $166,000, or $0.01 per diluted share, compared to $491,000, or $0.02 per diluted share, in the fourth quarter last year. Diluted shares totaling 20.8 million and 20.2 million were used in the computations for the years 2007 and 2006, respectively.
For the full year 2007, total revenue increased 7% to $27.2 million, compared to $25.5 million for 2006. Revenue gains were driven by antibody sales, which increased 29% year-over-year, and food pathogen test kit sales, which increased 22%, as compared to 2006. These gains were offset by a 44% decrease in the Company's Ag/GMO product line in 2007 as compared to 2006, in keeping with the ongoing and expected diminishment of that line of business.
Gross margins were 60.4% for the full year 2007 compared to 54.1% for 2006.
Research and development costs for full year 2007 were 10.8% of revenues compared to 10.3% for 2006.
SG&A costs for full year 2007 were 44% of revenues compared to 42% for 2006. During 2007, the Company incurred additional sales and marketing expense associated with the launch of the new antibody catalog.
Pre-tax income for full year 2007 totaled $1.8 million, compared to $966,000 for the same period in 2006. Net income for full year 2007 was $860,000, or $0.04 per diluted share, compared to $684,000, or $0.03 per diluted share, for last year. Diluted shares totaling 20.6 million and 20.1 million were used in the computations for the years 2007 and 2006, respectively.
Antibody revenues increased by 28% to $3.8 million in the fourth
quarter of 2007 compared to the same period in 2006 as the GAT platform
continues to expand. For full year 2007, a
|SOURCE Strategic Diagnostics Inc.|
Copyright©2008 PR Newswire.
All rights reserved